

**DNDi Drugs for Neglected Diseases initiative
India Foundation**

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

DIRECTORS' REPORT

Dear Members

Your directors have the pleasure to present the Sixth report of the directors (the "Report") of your Company together with the Audited Annual Accounts for the financial year ended 31st March 2022.

Financial Highlights

Particulars	(Figures in Rs.)	
	Financial Year ended on March 31, 2022	Financial Year ended on March 31, 2021
Total Income	33,28,737	1,995
Total Expenditure	1,52,181	64,750
Surplus (Deficit) for the year	31,76,556	(62,755)
Less: Current tax	0.00	0.00
Surplus (Deficit) after tax	31,76,556	(62,755)
Add: Balance as per last Balance Sheet	(1,16,585)	(53,830)
Balance Transferred to Balance Sheet	30,59,971	(1,16,585)

State of Company's Affairs

DNDi Drugs for Neglected Diseases Initiative India Foundation ('the Company'), a not-for-profit company, within the meaning of section 8 of the Companies Act 2013. The prime focus of the Company is to provide support and to stimulate research and development, primarily of drugs, as well as vaccines and diagnostics for patients suffering from neglected diseases.

During the year, your company was able to raise funds of Rs.33,01,557.00 through donation and also a CSR grant of Rs.7,00,000/- was received during the year. Now with sufficient funds available with Company, your company is planning to carry out its activities at large scale in coming years.

Your Company has filed an application for prior permission under FCRA for receiving foreign grant/donation which is pending for granting of approval as on date.

Once FCRA permissions is in place, Your Directors are optimistic about company's operations and hopeful of better performance with increased grants/donations in coming year/s.

Material changes and commitment, if any, affecting the financial position of the Company

Save as mentioned elsewhere in this Report, no material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the Company and the date of this Report.

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Public Deposits

During the year under review, your Company did not accept any deposits in terms of the provisions of section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

Number of meetings of the Board held during the financial year and attendance by Directors

During the year under review, two Board meetings were held on Aug 24th, 2021 & February 8th, 2022. The details of the Board meetings attended during the financial year by the Directors of the Company are as follows:

Date of the Board meeting	Lalit Kant	Shyam Sundar Agrawal	Ms Farhat Mantoo
Aug 24 th , 2021	Yes	Yes	NA
Feb 8 th , 2022	Yes	NA	Yes

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

A. Conservation of energy: Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.

B. Technology absorption: Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.

C. Foreign exchange earnings and Outgo:

Earnings in foreign exchange (actual inflows):	Nil
Expenditure in foreign currency (actual outflows):	Nil

Transfer to reserves

No amount was transferred to the reserves during the financial year ended 31st March 2021.

Particulars of contracts or arrangements made with related parties

The Company did not enter into any contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013.

Particulars of loans, guarantees or investments made under section 186 of the Companies Act, 2013

The Company did not provide any loan, guarantee or investment pursuant to section 186 of the Companies Act, 2013.

DNDi Drugs for Neglected Diseases *initiative*
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Directors and Key Managerial Personnel

Ms. Farhat Mantoo (DIN: 09278135) was appointed as Director of the Company in the Annual General Meeting of the Company held on 7th Sep. 2021 and Dr. Shyam Sundar Agrawal (DIN:07701481) resigned from the directorship w.e.f. 28th September 2021.

Statement of particulars of employees pursuant to provisions of rule 5(2) & (3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

The Company had no employees during the year under review.

Directors' Responsibility Statement

In terms of the provisions of section 134 (5) of the Companies Act, 2013, and to the best of their knowledge and belief and according to the information and explanations obtained by them and save as mentioned elsewhere in this Report, the attached Annual Accounts and the Auditors' Report thereon, your Directors confirm that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis; and
- (e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

DNDi Drugs for Neglected Diseases *initiative*
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Auditors

M/s Singh K.V. Gupta & Co Chartered Accountants were appointed as Statutory Auditors for a period of 5 years in the First Annual General Meeting held in 2017 and are retiring in forthcoming Annual General Meeting. They are eligible for reappointment for next 5 yrs, subject to approval of members at ensuing Annual General Meeting of the company. The Company has received a consent letter for re-appointment and a declaration about their eligibility for appointment. The Board of Director of the Company has recommended their appointment for next 5yrs.

Auditors' Report

The Auditor's Report for the period has been annexed with this report and the comments made by the Statutory Auditors in the Auditor's Report are self-explanatory.

Statement concerning development and implementation of risk management policy of the Company

In the opinion of the Board of Directors of the Company, no risks which may threaten the existence of the Company have been identified and therefore no risk management policy has been framed.

Subsidiaries, joint ventures and associate Companies

The Company does not have any Subsidiary, Joint Venture or Associate Company.

Details of significant & material orders passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future

No significant & material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

Adequacy of internal financial controls

The Company has in place adequate internal financial controls with reference to financial statements. During the year under review, such controls were tested and no reportable material weakness in the design or operation were observed.

DNDi Drugs for Neglected Diseases *initiative*
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Maintenance of cost records

The Company is not required to maintain cost records as specified by the Central Government under section 148(1) of the Companies Act, 2013.

Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013


The Company is not required to constitute Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Acknowledgment

Your directors take this opportunity to place on record their sincere appreciation for the co-operation and assistance the Company has received from banks and various Government Departments.

For and on behalf of the Board of Directors of

DNDi Drugs for Neglected Diseases Initiative India Foundation



(Lalit Kant)
Director
DIN: 07242018
Address: B-95, Block B, Gulmohar Park,
New Delhi – 110049, India
Date: August 18th, 2022
Place: New Delhi



(Farhat Marfoo)
Director
DIN: 09278135
Address: L-6, Third Floor, Lajpat Nagar-II
New Delhi -110024, India
Date: August 18th, 2022
Place: New Delhi

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI-110049
(A Private Company limited by guarantee under section 8 of the Companies Act 2013)

Balance Sheet As On 31st March, 2022

Particulars	Note No.	Figures in Hundred	
		Figures as at the end of current reporting period Rs.	Figures as at the end of previous reporting Period Rs.
A EQUITY AND LIABILITIES			
1 Member's funds			
(a) Reserves and surplus	1	30,600	-1,165
Total Members Fund		30,600	-1,165
2 Current liabilities`			
(a) Other current liabilities	2	8,163	1,213
(b) Short-term provisions	3	590	578
Total Current Liabilities		8,753	1,790
TOTAL EQUITY & LIABILITIES		39,352	624
B ASSETS			
1 Non-current assets			
(i) Property, Plant and Equipment	4		
(ii) Intangible assets		7	10
(iii) Capital Work in progress		-	-
(iv) Intangible Assets under Development		-	-
Total Non Current Assets		7	10
2 Current assets			
(a) Cash and cash equivalents	5	39,084	544
(b) Short-term loans and advances	6	260	70
Total Current Assets		39,345	614
TOTAL ASSETS		39,352	624

See accompanying notes forming part of the financial statements in terms of our report of even date attached.

For Singh K V Gupta & Co
Chartered Accountants
(FRN: 000133N)

FOR DNDI Drugs for Neglected Diseases Initiative India Foundation


CA. Rakesh Agarwal

Partner
M.No. 085908

Place: New Delhi

Date: 18th Aug, 2022

UDIN: 22085908AQLHIN9775



Lalit Kant

Lalit Kant
(DIRECTOR)
DIN -07242018

Farhat Mantoo

Farhat Mantoo
(DIRECTOR)
DIN: 09278135

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION			
PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI-110049			
(A Private Company limited by guarantee under section 8 of the Companies Act 2013)			
STATEMENT OF INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31st MARCH 2022			
(Figures in hundreds)			
Particulars	Note No.	Figures for the current reporting period	Figures for the previous reporting period
		Rs.	Rs.
Income			
I Donation Received	7	33,016	-
II Other Income	8	272	20
III Total Income (I+II)		33,287	20
IV Expenses			
(f) Depreciation and amortisation expenses	4	3	4
(g) Other expenses	9	1,519	644
Total Expenses		1,522	648
V Profit before exceptional and extraordinary item and tax		31,766	(628)
VI Exceptional Items		-	-
VII Profit before extraordinary item and tax		31,766	(628)
VIII Extraordinary Items		-	-
IX Profit before Tax		31,766	(628)
X Tax Expense:			
(a) Current tax expense		-	-
(b) Deferred tax		-	-
XI Surplus /(Defecit)for the period from continuing operations		31,766	(628)
XII Surplus / (Defecit) from discontinuing operations		-	-
XIII Tax from discontinuing operations		-	-
XIV Surplus/ (Defecit) from discontinuing operations		-	-
XV Surplus/(Defecit) for the Period		31,766	(628)
XVI Earning per equity share:			
(1) Basic		-	-
(2) Diluted		-	-

In terms of our report of even date attached.

For Singh K V Gupta & Co

Chartered Accountants

(FRN: 000133N)

CA. Rakesh Agarwal

Partner

M.No. 085908

Place: New Delhi

Date: 18th Apr. 2022

FOR DNDI Drugs for Neglected Diseases Initiative India Foundation

Lalit Kant

(DIRECTOR)

DIN -07242018

Farhat Mantoo

(DIRECTOR)

DIN: 09278135

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company limited by guarantee under section 8 of the Companies Act 2013)
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2022

Rupees in hundreds

	YEAR ENDED 31-03-2022	YEAR ENDED 31-03-2021
A CASH FLOW FROM OPERATING ACTIVITIES		
SURPLUS/DEFICIT BEFORE TAX AND EXTRAORDINARY ITEMS	31,766	-628
ADJUSTMENT FOR		
DEPRECIATION	3	4
DEPRECIATION RESERVE	0	0
FINANCE CHARGES	0	0
INTEREST ON BANK DEPOSIT/ LOANS & ADVANCE	-272	-20
PROVISION FOR INCOME TAX	0	0
DEFERRED TAX ASSETS	0	0
TAX ON DIVIDEND	0	0
CAPITAL CHANGES	31,496	-644
ADJUSTMENT FOR		
(INCREASE) / DECREASE IN SUNDRY DEBTORS	0	0
INCREASE) / DECREASE IN INVENTORIES	0	0
(INCREASE) / DECREASE IN CURRENT ASSETS	-191	6
(INCREASE) / DECREASE IN LOANS & ADVANCES	0	0
INCREASE / (DECREASE) IN CURRENT LIABILITIES	6,963	-163
NET CASH FLOW FROM OPERATING ACTIVITIES	36,268	-801
B CASH FLOW FROM INVESTING ACTIVITIES		
ADDITION TO FIXED ASSETS	0	0
SALE OF FIXED ASSETS	0	0
ADDITION TO WORK IN PROGRESS	0	0
INTEREST ON BANK DEPOSITS / LOANS & ADVANCES	272	20
NET CASH USED IN INVESTING ACTIVITIES	272	20
C CASH FLOW FROM FINANCING ACTIVITIES		
SHARE CAPITAL	0	0
SHARE APPLICATION MONEY PENDING ALLOTMENT	0	0
INVESTMENTS	0	0
DIVIDEND AND TAX ON DIVIDEND PAID	0	0
INCOME TAX PAID	0	0
FINANCING CHARGES	0	0
NET CASH GENERATED/USED FROM FINANCING ACTIVITIES	0	0
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	38,540	-781
CASH & CASH EQUIVALENTS AS AT OPENING DATE	544	1,325
	39,084	544
CASH & CASH EQUIVALENTS AS AT CLOSING DATE	39,084	544

As per our report of even date attached
For Singh K. V. Gupta & Co.
Chartered Accountants
FRN 000133N

For & on behalf of the Board

(CA Rakesh K Agarwal)
Partner

Membership No. 085908
Place : New Delhi

Date: 18/11/2022

Lalit Kant Farhat Mantoo
Director Director

DIN:07242018 DIN:09278135

**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
NOTES ANNEXED TO AND FORMING PART OF THE BALANCE SHEET**

Note 1 RESERVES AND SURPLUS

(In Hundreds)

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting Period
	Rs.	Rs.
Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	(1,165)	(538)
Add: Profit / (Loss) for the year	31,766	(628)
Closing balance	30,600	(1,165)

Note 2 OTHER CURRENT LIABILITIES

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting Period
	Rs.	Rs.
Expenses Payable	1,163	1,213
Others-CSR Grant (Unutilized)	7,000	-
Total	8,163	1,213

Note 3 SHORT TERM PROVISIONS

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting Period
	Rs.	Rs.
(a) Provision - for TAX		
TDS Payable	50	38
(b) Provision - Others		
Audit Fees Payable	540	540
Total	590	578



Note - 4

**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
STATEMENT OF FIXED ASSETS, AS ON 31ST MARCH 2022**

PARTICULARS	RATE OF DEPRECIATION	G R O S S B L O C K						DEPRECIATION				N E T -- B L O C K	
		AS ON	ADDITIONS Before 30.09.2021	ADDITIONS After 30.09.2021	SALE during the year	AS ON 31.3.2022	UP TO 01.04.2021	FOR THE YEAR	AS ON 31.03.2022	AS ON 31.03.2022	AS ON 31.03.2021	AS ON 31.03.2022	AS ON 31.03.2021
Furniture & Fixtures	25.89%	34	-	-	-	34	24	3	26	7	10	10	
TOTAL		34	-	-	-	34	24	3	26	7	10	10	
PREVIOUS YEAR		34	-	-	-	34	20	4	24	10	14	14	




Note 5 CASH AND CASH EQUIVALENTS**(In Hundreds)**

Particulars	0	0
	Rs.	Rs.
A) Cash In Hand	-	-
B) Bank Balance	39,084	544
Total	39,084	544

Note 6 SHORT TERM LOANS AND ADVANCES

Particulars	0	0
	Rs.	Rs.
Others Receivable	66	66
Interest Receivable	194	3
Total	260	70



Note 7 REVENUE FROM OPERATIONS		(IN HUNDREDS)	
Particulars	Figures for the current reporting period	Figures for the previous reporting period	
	Rs.	Rs.	
Donation Received	33,016	-	
Total - Sales	33,016	-	

Note 8 OTHER INCOME

Particulars	Figures for the current reporting period	Figures for the previous reporting period	
	Rs.	Rs.	
Interest Received	272	20	
Total	272	20	

Note 9 OTHER EXPENSES

Particulars	Figures for the current reporting period	Figures for the previous reporting period	
	Rs.	Rs.	
INDIRECT EXPENSES			
Professional Fees	-	50	
Consultancy Charges	500	-	
Audit Fees	590	590	
Travelling Expenses-Consultants	305	-	
Recruitment Expenses	41	-	
Interest on TDS	1	-	
Filing Fees	67	4	
Miscellaneous Exps	15	-	
Total	1,519	644	



DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company Limited by Guarantee under section 8 of the Companies Act, 2013)
PHD Chambers, 3rd Floor, 4/2, Institutional Area, August Kranti Marg, New Delhi-110016
Tel.: - 011-45501795

Note – 10: SIGNIFICANT ACCOUNTING POLICIES:

A: ACCOUNTING CONCEPT

The accounts are prepared on historical cost convention on accrual basis and also on a going concern basis in accordance with Generally Accepted Accounting Principles and accounting standards applicable in India as applicable under section 133 of the Companies Act 2013 read with MCA General Circular No. 15/2013 dated 13th September 2013 and other relevant provision of the Indian Companies Act 2013 read with the Companies (Accounts) Rules. 2014 except where otherwise stated.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with the generally accepted accounting practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Actual results could differ from those estimates. Differences between the actual results and estimates are recognised in the year in which the results are known/ materialized. Any revision to accounting estimates is recognised prospectively in current and future periods.


Contingencies are recorded when it is probable that a liability will be incurred, and the amount can be reasonably estimated.

C: FIXED ASSETS AND DEPRECIATION

Fixed Assets are stated at their original cost including freight, duties, customs and other incidental expenses relating to acquisition, installation and construction. Depreciation has been provided on written down value method over the useful life of Assets as specified in Schedule-II to the Companies Act 2013

D: REVENUE RECOGNITION

- 1) Grants, donations and service charges are recognized in the financial statements only when the same are sanctioned by the concerned agencies and received by the Company.
- 2) Interest on saving banks is recognized whenever same is credited by bank in the account of the Company.
- 3) Grants received for specific projects are recognized as income to the extent utilized during the year as per the terms of agreement/ sanction/confirmation and unutilized



amounts are carried forward and disclosed under Current Liabilities until the actual expenditure is incurred. Amount spent more than the grant amount received for specific project are accounted for as receivable from the Grantor

E: Grants made to projects carried out through partner agencies are accounted for on the basis of utilization certificate/statement submitted by the grantees.

F: FOREIGN EXCHANGE TRANSACTIONS

Transactions in foreign currencies are recorded at the rate at which credit/ debit is given by the bank at the time of occurrence of the transaction.

G: PROVISIONS

A provision is recognized when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

H: OTHERS

Accounting Policies not specifically referred to otherwise are consistent with generally accepted accounting principles followed by the Company.



NOTES TO THE ACCOUNTS:

A: This is the Sixth Year of the Company as the Company was incorporated on 27th May 2016 as a private company limited by guarantee and not having a share capital and was granted a license no. 107097 dated 23rd May 2016 under section 8(1) of the Companies Act, 2013, by Government of India- Ministry of Corporate Affairs. The Company has been granted registration under section 12AA of the Income Tax Act 1961 vide letter no CIT (E)/DEL-DR26044-23032017/7387 dated 23rd March 2017 & approval under section 80-G of the Income Tax Act 1961 vide letter no. CIT(E)/DEL-DE27667-23032017/8506 dated 23rd March 2017 by Commission of Income Tax (Exemption) Delhi. During the year, Company has applied for prior permission under Foreign Contribution Regulation Act for receiving foreign grants/donation. This application is still pending for disposal.

B: Foreign Exchange Earning & Out – Go.

Particulars	Current Year	Previous Year
Earning	0.00	0.00
Out – Go (Foreign Travel Exp.)	0.00	0.00

C: Related Party Transactions

In the normal course of business, the Company enters into transactions with key management personnel. The names of related parties of the Company and their relationship, as required to be disclosed under Accounting Standard 18 are as follows:

a) Related party and nature of related party relationship with whom transaction have taken place during the year

Relationship	Name of the related party
Key Management Personnel	Dr Lalit Kant-Director
Key Management Personnel	Dr Farhat Mantoo-Director

b) Summary of Significant transaction and outstanding balances with related parties (Figures in lakhs)

Name of the related party	Nature of Transaction	Current year	Previous year	Outstanding as on 31 st Mar 22	Outstanding as on 31 st Mar 21
-	-	0.00	0	0	0

D: Amount due from Director Rs.NIL

E: Provision for taxation has not been made in accounts in the absence of any income.

F: The Company is a Small and Medium Sized Company (SMC) as defined in the General



Instructions in respect of Accounting Standards notified under the Companies Act, 1956. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

- G.** The Company has not provided nor taken any loan or advance to/from any other person or entity or invested any funds or provided any guarantee or security with understanding that benefit of the transaction will go to a third party, the ultimate beneficiary.
- H.** The Company has not received any funds from any person(s) or entity(ies), including foreign entities (the Funding Parties), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

I. OTHER STATUTORY INFORMATION

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- (ii) The Company does not have any transactions with companies struck off.
- (iii) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.
- (iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (iv) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

J-RATIO

Ratios	Numerator	Denominator	Current Reporting Period	Previous reporting period	% of Change	Reason for Variance
Current Ratio	Current Assets	Current Liabilities	4.50	0.34	1,210.17	Increase due to significant increase in Current assets due to increase in bank balance on account of receipt of donation/grants
Debt Equity Ratio	Debt Capital	Shareholder's Equity	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.
Debt Service coverage ratio	EBITDA-CAPEX	Debt Service (Int+Principal)	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.
Return on Equity Ratio	Profit for the year	Average Shareholder's Equity	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.
Inventory Turnover Ratio	COGS	Average Inventory	0.00	0.00	0.00	N.A.as per the nature and activities of the



Trade Receivables turnover ratio	Net Sales	Average trade receivables	0.00	0.00	0.00	Company. N.A as there is no trade receivable
Trade payables turnover ratio	Total Purchases (Fuel Cost + Other Expenses+Closing Inventory-Opening Inventory)	Closing Trade Payables	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.
Net capital turnover ratio	Grants & Donation	Working capital (CA-CL)	107.92%	0.00	100%	Due to increase in Grant & Donations
Net profit ratio	Net Profit	Grants & Donation	96.21%	0.00	96.21%	Due to increase in Grant & Donations. There was net loss in previous year
Return on Capital employed	Earnings before interest and tax	Capital Employed	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.
Return on investment	Net Profit	investment	0.00	0.00	0.00	N.A.as per the nature and activities of the Company.

K Previous year's figures have been regrouped/ reclassified, wherever necessary, to conform to the current year's presentation

L: Notes A to G form an integral part of the balance sheet and income & expenditure account.

**For and on behalf of the Board of Directors
Of DNDI Drugs for Neglected Diseases Initiative India Foundation**


Lalit Kant
Director
DIN:07242018


Farhat Mantoo
Director
DIN:09278135

Date: 18th Aug. 2022
Place: New Delhi





SINGH K. V. GUPTA & CO

INDEPENDENT AUDITORS' REPORT CHARTERED ACCOUNTANTS

To

The Members

DNDI Drugs for Neglected Diseases Initiative India Foundation

New Delhi

Report on the audit of the financial statements

Opinion

We have audited the accompanying financial statements of **DNDI Drugs for Neglected Diseases Initiative India Foundation** ("the Company"), which comprise the balance sheet as at March 31, 2022, and the Statement of Income and Expenditure and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, its surplus and cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context



7/38, Ansari Road, Daryaganj, New Delhi-110002

Tel. No. 011-40394905, 011-23260728(Telefax), e-mail: skvgca@gmail.com

of our audit of the financial statements as a whole, and informing our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's responsibility for the financial statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The board of directors are also responsible for overseeing the Company's financial reporting process.



Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we




determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

1) The provisions of the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not applicable to the Company as the Company is to licensed operate u/s 8 of the Companies Act 2013. As required by Section 143(3) of the Act, we report that:


- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The balance sheet, the statement of profit and loss, and the cash flow statement dealt with by this report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;
- (e) On the basis of the written representations received from the directors as on March 31, 2022 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;
 - a. The Company does not have any pending litigations which would impact its financial position;
 - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
 - c. There has been no delay in transferring amounts, required to be



transferred, to the Investor Education and Protection Fund by the Company

- d. (i) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- (ii) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- e. Since the Company is registered under section 8 of the Act as a Company with charitable objects, it cannot declare any dividend and accordingly, reporting under Rule 11(f) is not applicable to the Company.

For Singh K V Gupta & Co
Chartered Accountants
Firm Registration No.000133N


CA. Rakesh Agarwal
Partner
Membership No.0859087
UDIN : 22085908AQLHIN9775
Place: New Delhi
Date:18th August 2022



Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 2 (f) under 'Report on other legal and regulatory requirements' section of our report to the Members of **DNDI Drugs for Neglected Diseases Initiative India Foundation** of even date)

Report on the internal financial controls over financial reporting under clause (i) of sub – section 3 of section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **DNDI Drugs for Neglected Diseases Initiative India Foundation** ("the Company") as at March 31, 2022, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's responsibility for internal financial controls

The board of directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the standards on auditing prescribed under Section 143 (10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those standards and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence



about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement in the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial control system over financial reporting.

Meaning of internal financial controls over financial reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of internal financial controls over financial reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management of override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



Opinion

In our opinion and according to the information and explanations given to us, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering



the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Singh K V Gupta & Co
Chartered Accountants
Firm Registration No 000133N



CA Rakesh Agarwal
Partner
Membership No. 085908
UDIN : 22085908AQLHIN9775
Place: New Delhi
Date: 18th August 2022